Fosun: Foreign Media Reports about "Regulatory Authorities Asking Banks to Examine their Exposure to Fosun" are Completely False
HONG KONG, Sept. 14, 2022 /PRNewswire/ -- In response to foreign media reports about "Chinese regulatory authorities asking banks and some of the state-owned companies to examine their exposure to Fosun" on 13 September, Fosun said such reports are completely false.
It is understood that Fosun has sought confirmation from regulatory authorities through multiple channels. The China Banking and Insurance Regulatory Commission (CBIRC) has not asked commercial banks to check about their financial exposure on Fosun, and many commercial banks that cooperate with Fosun have never received relevant notices.
Gong Ping, Executive President and CFO of Fosun International, said, "Fosun's recent seemingly frequent reductions in shareholdings and divestments are a continuation of its financial strategy of balancing investment and divestment in the past few years. Fosun has been dynamically sorting and optimizing its asset portfolios. Such moves are not just for coping with the current market environment. However, we noticed that the complex external environment has raised public opinion on the disposal of the Group's assets, resulting in a one-sided interpretation of such asset disposal, while neglecting the Group's general principle of asset optimization, which is our long-term dynamic asset optimization."
According to the interim results announced on 30 August, Fosun's four major business segments of Health, Happiness, Wealth, and Intelligent Manufacturing demonstrated resilience. In the first half of the year, Fosun achieved sustainable revenue growth, its total revenue reached RMB82.89 billion, representing a year-on-year increase of 17.7%. Its enterprise operation profit increased by 35.5% year-on-year. Meanwhile, the Group's funds remained stable. As at the end of the reporting period, cash, bank balances and term deposits were abundant, amounting to RMB117.65 billion; the adjusted NAV remained stable at HK$24.2 per share.
Upcoming Life Sciences Events
- November 2022
- Biotechgate Digital Partnering November 2022
- February 2023
- Biotechgate Digital Partnering February 2023
- May 2023
- 10785 Berlin: Global Bioprocessing Summit & Exhibition